Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Mizuho has reaffirmed its Buy rating on MiMedx Group (NASDAQ:MDXG) and increased its price target from $13.00 to $14.00. MiMedx Group's shares have risen by 0.98% in the last 24 hours to $8.24. The new price target suggests a potential upside of 69.9%. MiMedx Group specializes in developing and marketing regenerative biomaterial products and bioimplants derived from human tissues, targeting various medical fields.
March 01, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho reaffirms Buy rating on MiMedx Group, raising price target from $13 to $14. Shares have risen by 0.98% to $8.24, with the new target suggesting a 69.9% upside.
The reaffirmation of the Buy rating and the increase in price target by Mizuho are strong positive signals for MiMedx Group. Given the company's specialization in regenerative biomaterials and the potential for significant share price appreciation as indicated by the new price target, this news is likely to have a positive short-term impact on MDXG's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100